Sanofi

Oita Chuo Pacific Management Comments on Sanofi as They Agree to Acquire U.S. Biotech Firm Principia Biopharma

Retrieved on: 
Monday, August 17, 2020
Biotechnology, Finance, Health, Professional services, Pharmaceutical, Companies, CAC 40, Sanofi, Ōita

According to data collected by Oita Chuo Pacific Management , the all-cash-deal will see Sanofi take full ownership of the company, which focuses on therapies for multiple sclerosis and a host of autoimmune conditions.

Key Points: 
  • According to data collected by Oita Chuo Pacific Management , the all-cash-deal will see Sanofi take full ownership of the company, which focuses on therapies for multiple sclerosis and a host of autoimmune conditions.
  • The cumulative equity value of the deal is estimated at $3.7 billion," commented Head of Wealth Management at Oita Chuo Pacific Management , Jonathan Marshall.
  • Principia is a perfect match for Sanofi," commented Michael Knight, Head of Corporate Equities at Oita Chuo Pacific Management .
  • Oita Chuo Pacific Management is a recognized leader in wealth management advisory with offices located in the heart of Tokyo, Japan.

Sanofi to acquire Principia Biopharma

Retrieved on: 
Monday, August 17, 2020
Companies, CAC 40, Sanofi, Principia

PARIS and SOUTH SAN FRANCISCO, Calif., Aug. 17, 2020 /PRNewswire/ -- Sanofi and Principia Biopharma Inc. (NASDAQ: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Principia for $100 per share in cash, which represents an aggregate equity value of approximately $3.68 billion (on a fully diluted basis).

Key Points: 
  • PARIS and SOUTH SAN FRANCISCO, Calif., Aug. 17, 2020 /PRNewswire/ -- Sanofi and Principia Biopharma Inc. (NASDAQ: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Principia for $100 per share in cash, which represents an aggregate equity value of approximately $3.68 billion (on a fully diluted basis).
  • The Sanofi and Principia Boards of Directors unanimously approved the transaction.
  • The merger will provide global resources to get these novel therapies to patients faster,"said Martin Babler, President and CEO at Principia Biopharma.
  • In 2017, Sanofi formed a collaboration with Principia under which Principia granted Sanofi an exclusive, worldwide license to develop and commercialize BTK inhibitor '168 in multiple sclerosis and other central nervous system diseases.

Sanofi to acquire Principia Biopharma

Retrieved on: 
Monday, August 17, 2020
Companies, CAC 40, Sanofi, Bruton's tyrosine kinase

The Sanofi and Principia Boards of Directors unanimously approved the transaction.

Key Points: 
  • The Sanofi and Principia Boards of Directors unanimously approved the transaction.
  • By combining with Sanofi, we will bring significant resources to expand and accelerate the potential benefits of these therapies.
  • The merger will provide global resources to get these novel therapies to patients faster, said Martin Babler, President and CEO at Principia Biopharma.
  • In 2017, Sanofi formed a collaboration with Principia under which Principia granted Sanofi an exclusive, worldwide license to develop and commercialize BTK inhibitor 168 in multiple sclerosis and other central nervous system diseases.

Zomedica Announces Second Quarter 2020 Financial Results

Retrieved on: 
Monday, August 10, 2020
Anatomy, Endocrine system, Branches of biology, Thyroid, Glycoproteins, Pituitary gland, Sanofi, Thyroid-stimulating hormone, TSH

ANN ARBOR, Mich., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (Zomedica or Company), a veterinary health company, today reported consolidated financial results for the second quarter ended June 30, 2020.

Key Points: 
  • ANN ARBOR, Mich., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (Zomedica or Company), a veterinary health company, today reported consolidated financial results for the second quarter ended June 30, 2020.
  • In May 2020, Zomedica announced verification completion of feline tT4, and canine and feline TSH (thyroid stimulating hormone).
  • In June 2020, Zomedica announced the appointment of Robert Cohen as its new Interim Chief Executive Officer.
  • The decrease resulted primarily from a lower net loss in the second quarter of 2020 compared to the second quarter of 2019, offset in part by a reduction of current liabilities.

Bayer Names Lori Moore as Vice President, Head of U.S. Pharmaceutical Communications

Retrieved on: 
Monday, August 10, 2020
Research, Fitness & Nutrition, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Companies, Industries, Health, IG Farben, Deloitte, Bayer, Novo Nordisk, Nordisk, Sanofi, Pharmaceutical industry

Lori Moore, former Managing Director at Deloitte, will be joining Bayer as Vice President, Head of Pharmaceutical Communications in the United States, the company announced today.

Key Points: 
  • Lori Moore, former Managing Director at Deloitte, will be joining Bayer as Vice President, Head of Pharmaceutical Communications in the United States, the company announced today.
  • Prior to joining Deloitte, Moore served in communications leadership positions at Novo Nordisk and Sanofi.
  • Im delighted to have Lori join the Bayer team as she brings more than 20 years of experience in the pharmaceutical industry, Kerins said.
  • Throughout her career, Moore has served in various positions leading marketing communications, corporate branding, internal communications and public relations.

Denali Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights

Retrieved on: 
Friday, August 7, 2020
Companies, Life sciences, Industries, Spinal muscular atrophy, Biogen, Sanofi, Denali Depot

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2020 and provided business highlights.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2020 and provided business highlights.
  • Should the LRRK2 program achieve certain development and commercial milestones, Denali will be eligible to receive up to $1.125 billion in potential milestone payments.
  • Outside the U.S. and China, Biogen will be responsible for commercialization and pay Denali tiered royalties.
  • Denali and Sanofi have paused DNL747 and switched to DNL788, with plans to initiate a clinical study around year-end 2020.

Principia Biopharma Reports Second Quarter 2020 Financial Results

Retrieved on: 
Thursday, August 6, 2020
Companies, Life sciences, Industries, CAC 40, Sanofi

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc.(Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, today announced financial results for the second quarter ended June 30, 2020.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc.(Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, today announced financial results for the second quarter ended June 30, 2020.
  • We are very pleased with the progress the company made on each program in the first half of the year despite the ongoing COVID-19 pandemic challenges.
  • In addition, the company received an additional $50.0 million milestone payment from Sanofi in the third quarter of 2020.
  • Principia is a late-stage biopharmaceutical company dedicated to bringing transformative therapies to patients with significant unmet medical needs in immune mediated diseases.

Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis

Retrieved on: 
Wednesday, August 5, 2020
Medical specialties, Health, Medicine, Breakthrough therapy, Ofatumumab, Immunosuppressants, Sanofi, Immunology, Novartis, Multiple sclerosis, Teriflunomide, Monoclonal antibody

Regulatory approval for ofatumumab in the US is expected in September 2020 and in Europe by Q2 2021.

Key Points: 
  • Regulatory approval for ofatumumab in the US is expected in September 2020 and in Europe by Q2 2021.
  • Novartis is committed to bringing ofatumumab to patients worldwide and additional regulatory filings are currently underway.
  • Onset of B-cell depletion with subcutaneous administration of ofatumumab in relapsing multiple sclerosis: results from the APLIOS bioequivalence study.
  • Ofatumumab versus teriflunomide in relapsing multiple sclerosis: baseline characteristics of two pivotal phase 3 trials (ASCLEPIOS I and ASCLEPIOS II).

Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine

Retrieved on: 
Friday, July 31, 2020
Vaccines, Health, Drugs, Medical research, RTT, CAC 40, Sanofi, COVID-19 vaccine, Influenza vaccine, Vaccine, H5N1 clinical trials, H5N1 vaccine

PARIS and LONDON July 31, 2020 Sanofi and GSK are in advanced discussions, with the European Commission (EC) for the supply of up to 300 million doses of a COVID-19 vaccine.

Key Points: 
  • PARIS and LONDON July 31, 2020 Sanofi and GSK are in advanced discussions, with the European Commission (EC) for the supply of up to 300 million doses of a COVID-19 vaccine.
  • The vaccine candidate developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSKs established adjuvant technology.
  • Together with GSK, we are working relentlessly to develop and produce a vaccine to address this global health crisis.
  • Translate Bio has established mRNA manufacturing capacity and Sanofi expects to be able to supply annual capacity of 90 to 360 million doses.

COVID-19 Impacts: Allergy Rhinitis Drugs Market will Accelerate at a CAGR of almost 4% through 2020-2024 | Increasing Prevalence Of Allergic Rhinitis to Boost Growth | Technavio

Retrieved on: 
Thursday, July 30, 2020
General Health, Pharmaceutical, Health, Health care, Health, Medical specialties, Allergology, Rhinitis, ALK-Abelló, Novartis, Pfizer, Stallergenes Greer, Sanofi, Glenmark Pharmaceuticals, Pharmaceutical industry in China

Our allergy rhinitis drugs market report covers the following areas:

Key Points: 
  • Our allergy rhinitis drugs market report covers the following areas:
    This study identifies the rising awareness about allergic rhinitis as one of the prime reasons driving the allergy rhinitis drugs market growth during the next few years.
  • We provide a detailed analysis of around 25 vendors operating in the allergy rhinitis drugs market, including some of the vendors such as Alcon Inc., ALK-Abello AS, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, and Stallergenes Greer Ltd.
  • Backed with competitive intelligence and benchmarking, our research reports on the allergy rhinitis drugs market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Register for a free trial today and gain instant access to 17,000+ market research reports.